Lonza (OTCPK:LZAGF ... capabilities to meet demand for the next generation of mammalian biologics therapies. The products currently manufactured at the site by Roche (OTCQX:RHHBY) (OTCQX:RHHBF ...

Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel, ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

PORTSMOUTH — The Pease Development Authority’s Board of Directors voted to approve the concept plan for Lonza Biologics Inc., to install “canopy sunshades as an enhancement to the extended ...

MiscellaneousLonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST Lonza’s new simplified and streamlined operating model is designed to support its One Lonza ...

Under the terms of the new agreement, Lonza will manufacture the mAb at Lonza’s biologics facility in Porriño (ES), occupying a majority of the site’s manufacturing capacity. The ADC will then be ...

Lonza Group posted lower sales and earnings ... sales fell 2.1% to 6.57 billion Swiss francs ($7.27 billion) as growth in its biologics division couldn’t offset lower sales in its capsules ...